Your browser doesn't support javascript.
loading
Zhuang-Gu-Fang intervenes vasculogenic and osteogenic coupling in GK rats through Notch1/Noggin/VEGF pathway.
Jin, Xinyan; Sun, Yuyu; Bai, Rui; Shi, Jun; Zhai, Linna; Jiang, Yunxia; Jiang, Mengchun; He, Jiali; Li, Junyu; Wang, Ting; Li, Shuanglei; Chen, Wenhui.
Afiliación
  • Jin X; Graduate School, Guangxi University of Chinese Medicine, Nanning, 530001, China.
  • Sun Y; Graduate School, Guangxi University of Chinese Medicine, Nanning, 530001, China.
  • Bai R; Graduate School, Guangxi University of Chinese Medicine, Nanning, 530001, China.
  • Shi J; Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, Nanning, 530299, China.
  • Zhai L; School of Public Health and Management, Guangxi University of Chinese Medicine, Nanning, 530001, China.
  • Jiang Y; Department of Endocrine, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China.
  • Jiang M; Department of Endocrine, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China.
  • He J; Graduate School, Guangxi University of Chinese Medicine, Nanning, 530001, China.
  • Li J; Graduate School, Guangxi University of Chinese Medicine, Nanning, 530001, China.
  • Wang T; Graduate School, Guangxi University of Chinese Medicine, Nanning, 530001, China.
  • Li S; Graduate School, Guangxi University of Chinese Medicine, Nanning, 530001, China.
  • Chen W; Department of Endocrine, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China.
Heliyon ; 10(6): e28014, 2024 Mar 30.
Article en En | MEDLINE | ID: mdl-38524608
ABSTRACT

Background:

Zhuang-Gu-Fang (ZGF) has been proved to treat osteoporosis in ovariectomized rats by increasing osteogenic related factors Leptin, Ghrelin and Peptide YY(PYY). However, the mechanism of ZGF in the treatment of diabetic osteoporosis (DOP) remains unclear. The aim of this study was to explore the therapeutic effect of ZGF on DOP and its potential molecular mechanism.

Methods:

Using GK rats as models, the pharmacodynamic effects of ZGF on bone loss were evaluated by hematoxylin-eosin (H&E) staining and micro-computed.tomography (micro-CT). The expression levels of CD31 and endomucin (Emcn) were detected by immunofluorescence to assess the role of ZGF in angiogenic osteogenic coupling. Finally, real-time quantitative PCR (RT-PCR) and Western Blot (WB)were used to detect the expression levels of osteogenic and angiogenesis-related genes and proteins Notch1, Noggin and vascular endothelial growth factor (VEGF).

Results:

Administration of ZGF demonstrated a significant mitigation of bone loss attributable to elevated glucose levels. H&E staining and micro-CT showed that ZGF notably improved the integrity of the trabecular and cortical bone microarchitecture. Moreover, ZGF was found to augment the density of type H vessels within the bone tissue, alongside elevating the expression levels of Osterix, a transcription factor pivotal for bone formation. Furthermore, our findings suggest that ZGF facilitates the activation of the Notch1/Noggin/VEGF pathway, indicating a potential mechanism through which ZGF exerts its osteoprotective effects.

Conclusion:

Our results suggest that ZGF potentially facilitates the formation of type H vessels through the Notch1/Noggin/VEGF pathway. This action not only enhances angiogenic-osteogenic coupling but also contributes to the improvement of bone structure and density. Consequently, ZGF emerges as a promising therapeutic agent for the prevention and management of DOP, offering a novel approach by leveraging angiogenesis-dependent osteogenesis.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Heliyon Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Heliyon Año: 2024 Tipo del documento: Article País de afiliación: China
...